Current Key Issues in Transcatheter Aortic Valve Replacement Undergoing a Paradigm Shift

In-Chang Hwang, MD; Kentaro Hayashida, MD, PhD; Hyo-Soo Kim, MD, PhD

As a new technology in the management of valvular heart disease, transcatheter aortic valve replacement (TAVR) has drawn much attention since its emergence. To date, numerous studies have investigated the safety and efficacy of TAVR in patients of various risk profiles with severe aortic stenosis (AS) and demonstrated comparable or superior outcomes of TAVR when compared with surgical aortic valve replacement (SAVR). The favorable outcomes of TAVR in inoperable patients, as well as in high- and intermediate-risk patients, are endorsed in current guidelines, and trials of low-risk patients have shown non-inferior or even superior results of TAVR than for SAVR, suggesting that the clinical indications of TAVR can be expanded to low-risk patients. Moreover, a therapeutic role of TAVR has been suggested in various aortic valve (AV) diseases, such as bicuspid AV, moderate AS with heart failure, aortic regurgitation, and bioprosthetic valve failure. In this review, we summarize the current issues of TAVR in various patient populations and discuss the expanding clinical indications of TAVR, which are driving a major paradigm shift in the management of AV disease.

Key Words: Aortic stenosis; Surgical aortic valve replacement; Transcatheter aortic valve implantation; Transcatheter aortic valve replacement; Valve-in-valve

New technologies, according to the Gartner hype cycle theory, have 5 phases from conceptual presentation to generalized adoption.1 The introduction and distribution of transcatheter aortic valve replacement (TAVR), or transcatheter aortic valve implantation (TAVI), demonstrated similar patterns (Figure 1), but since its emergence, TAVR has been attracting much attention as an alternative to surgical aortic valve replacement (SAVR). Given the potential benefits of this noninvasive procedure and the unmet clinical need in real-world practice, clinicians and researchers imposed huge expectations and enthusiasm on TAVR (“peak of inflated expectations”), which was then criticized for the risk of complications and uncertainties about device durability and long-term prognosis (“trough of disillusionment”). These concerns were then rebutted with numerous studies from clinical trials and registries that reported favorable outcomes of TAVR, compared with SAVR (“slope of enlightenment”), and it is expected that ongoing trials with constructive discussion will clarify the optimal treatment strategy for applying TAVR in various AV diseases (“plateau of productivity”).

Currently, there are active debates regarding the clinical role, long-term durability, risk of complications, and expanding indications of TAVR in patients with low surgical risk, bicuspid AV, moderate aortic stenosis (AS) with heart failure (HF), and bioprosthetic valve failure. In this article, we summarize the current issues in TAVR, and review the expectations for expanding the clinical indications of TAVR with supporting evidence.

Current Treatment Strategy Guided by Surgical Risk Score

TAVR vs. SAVR or Standard Therapy According to Risk Scores

Early in the introduction of TAVR, its clinical role was demonstrated among inoperable patients with severe AS (Society of Thoracic Surgeons [STS] score >15%) and those with high surgical risk (STS score, 10–15%) (Table 1).2–5 Among intermediate-risk patients (STS score, 4–10%) with severe AS, large trials reported that TAVR resulted in similar, or even better, outcomes in terms of the risks of death and disabling stroke, hemodynamic parameters, hospital stay, and quality of life, compared with SAVR (Table 1).6–8 These findings indicate that TAVR was a reasonable alternative to SAVR for intermediate-risk patients with severe AS.2

Subsequently, the attentions at the front line of clinical practice turned to low-risk patients, and several studies showed acceptable outcomes in the low-risk patients that render optimistic expectations (Table 1).9–11 Although the outcomes of TAVR in low-risk patients had been questioned, the Evolut Low Risk trial showed that TAVR with Evolut-R was non-inferior to SAVR in terms of a composite of death or disabling stroke at 24 months among more than 1,400 patients with an average STS score of 1.9%.12

Received February 5, 2019; revised manuscript received March 12, 2019; accepted March 15, 2019; J-STAGE Advance Publication released online April 5, 2019

Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Gyeonggi-do (I.-C.H.); Cardiovascular Center, Department of Internal Medicine, Seoul National University Hospital, Seoul (I.-C.H., H.-S.K.), Korea; and Department of Cardiology, Keio University School of Medicine, Tokyo (K.H.), Japan

Mailing address: Hyo-Soo Kim, MD, PhD, FAHA, Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, 101 Daechak-ro, Jongno-gu, Seoul, 03080, South Korea. E-mail: hyosoo@snu.ac.kr

ISSN-1346-9843 All rights are reserved to the Japanese Circulation Society. For permissions, please e-mail: cj@j-circ.or.jp
According to the Optimized Catheter Valvular Intervention (OCEAN)-TAVI Japanese multicenter registry, the frailty score affects not only in-hospital outcomes but also post-discharge long-term prognosis. These findings suggest that frail patients have a potential TAVR-related futility. However, it should also be noted that refusal of TAVR, even only once, is associated with worse outcome. Because patients with advanced frailty cannot undergo surgery because of their extremely high peri-operative risk, the only available treatment option for them is TAVR. Therefore, an assessment of frailty in patients undergoing TAVR should not serve as a barrier for the procedure but rather should be used for proper periprocedural management, such as nutritional support or rehabilitation.

**Anatomic Complexity and Concerns With TAVR**

**Implications of AV Calcification**

The severity and location of AV calcification are important contributing factors to post-TAVR paravalvular leakage (PVL), because a heavily calcified native AV may prevent complete expansion of the device, even after balloon post-dilation. A study of 150 patients who underwent TAVR suggested that eccentricity of AV calcification (EoC) is associated with PVL risk. In that study, EoC at the AV leaflets was assessed using the maximum difference in calcification between any 2 adjacent leaflet sectors. This “leaflet-based EoC” might seem to be intuitive, but does not reflect true EoC in several situations that are common in severe AS patients. In this regard, our group developed a novel protocol for the assessment of EoC, called “bipartition EoC”, which indicates the maximum absolute difference in calcium volume between 2 sectors divided by a cutting line that passes through the center of the AV cusps. This method provides a simple but comprehensive...
reflection of the true EoC, especially in patients with balanced calcification at 2 or more leaflets, those with significant commissural calcification, and those for whom delineation of the AV leaflets is difficult (Figure 3). The bipartition EoC has a better predictive value for the occurrence of PVL, and response to balloon post-dilation, compared with conventional leaflet-based EoC. These findings highlight the importance of AV calcification and its eccentricity in determining the prosthesis type, device size, and whether to perform pre- and/or post-dilation during TAVR.17,18

It is expected that the new-generation devices will reduce the PVL risk, because they are mounted with outside fabric that can fill the gap between the device and AV calcification (Figure 4). These evolutionary changes provide optimism for a reduction in PVL without increasing the risk of aortic root injury. However, the use of balloon-expandable valves still requires attention, because of the need for high-pressure inflation during deployment, especially in patients with heavy AV calcification.19

### Bicuspid AV

Because of the anatomic characteristics of bicuspid AV, the application of TAVR in bicuspid AS raised negative expectations in terms of elliptical expansion of the device and the risks of coronary obstruction, residual PVL, and aortic root injury, which are attributable to structural characteristics (Supplementary Figure 1). Because of the fusion or raphe between AV leaflets, the actual size of the native AV opening is smaller than that of the aortic root, and device selection based on the aortic annulus can result in oversizing. Furthermore, the burden of AV calcification

---

**Table 1. Clinical Trials Comparing TAVR and SAVR, and Other Important Trials**

| Surgical risk | Clinical trial | Study size | Design | Device | Primary endpoint | Short-term outcomes | Mid- to long-term outcomes |
|---------------|----------------|------------|--------|--------|------------------|---------------------|---------------------------|
| Inoperable    | PARTNER 1B4    | 358        | TAVR vs. SAVR | Sapien | All-cause death | 1-year outcome: - TAVR: 30.7% (P<0.001) - Standard therapy: 50.7% | 5-year outcome: - TAVR: 71.8% (P<0.0001) - Standard therapy: 93.6% |
| High          | PARTNER 1A5    | 699        | TAVR vs. SAVR | Sapien | All-cause death | 1-year outcome: - TAVR: 24.2% - SAVR: 26.8% (P=0.44) | 5-year outcome: - TAVR: 67.8% - SAVR: 62.4% (P=0.76) |
| Intermediate  | PARTNER 2A6    | 2,032      | TAVR vs. SAVR | Sapien XT | All-cause death or disabling stroke | 2-year outcome: - TAVR: 19.3% - SAVR: 21.1% (P=0.25) [transfemoral access cohort] - TAVR: 16.8% - SAVR: 20.4% (P=0.05) | – |
|               | SRU TAVI6      | 1,746      | TAVR vs. SAVR | CoreValve Evolut-R | All-cause death or disabling stroke | 2-year outcome: - TAVR: 19.3% - SAVR: 21.1% (P=0.25) | – |
|               | CoreValve US Pivotal trial7 | 797 | TAVR vs. SAVR | CoreValve | All-cause death | 2-year outcome: - TAVR: 22.2% - SAVR: 28.6% (P=0.05) | – |
| Low           | NOTION All Comer8,9 | 280 | TAVR vs. SAVR | CoreValve | All-cause death | 2-year outcome (total): - TAVR: 8.0% - SAVR: 9.8% (P=0.54) [Composite endpoint in low-risk patients] | 6-year outcome: - TAVR: 42.5% - SAVR: 37.7% |
|               | Low Risk TAVR10 | 200 TAVR | Sapien 3 or Evolut-R | All-cause death at 30 days | 30-day death: - TAVR: 0% - SAVR: 1.7% | – |
|               | PARTNER 313    | 1,000      | TAVR vs. SAVR | Sapien 3 | All-cause death, all strokes, and rehospitalization | 1-year outcome: - TAVR: 8.5% - SAVR: 15.1% (P=0.031) | – |
|               | Evolut Low Risk12 | 1,468 | TAVR vs. SAVR | Evolut-R | All-cause death or disabling stroke | 2-year outcome: - TAVR: 5.3% - SAVR: 6.7% | – |
|               | NOTION 2 [NCT02825134] | 992 | TAVR vs. SAVR | Any approved device | All-cause death, MI, and stroke | Estimated primary completion date: June 2020 | – |

(Table 1 continued the next page.)
| Topic | Clinical trial | Study size | Design | Device | Primary endpoint | Details |
|-------|----------------|------------|--------|--------|------------------|---------|
| Moderate AS with HF | TAVR UNLOAD [NCT02661451] | 600 | TAVR vs. optimal HF therapy | Sapien 3 | All-cause death, disabling stroke, hospitalization related to HF, AV disease or non-disabling stroke, KCCQ | Estimated primary completion date: January 2020 |
| Asymptomatic severe AS | EARLY TAVR [NCT03042104] | 1,109 | TAVR vs. clinical surveillance | Sapien 3 | All-cause death, all strokes, and unplanned cardiovascular hospitalizations | Estimated primary completion date: December 2021 |
| | EVoLVeD trial [NCT03094143] | 1,000 | Early intervention (TAVR or SAVR) vs. routine care vs. no follow-up | Any approved device | All-cause death or unplanned AS-related hospitalization | Estimated primary completion date: July 2022 |
| | | | | | Screening for LV decompensation: troponin or ECG Confirmation of LV decompensation with CMR: mid-wall fibrosis - Intervention: early intervention with TAVR or SAVR (group A) - Comparator #1: routine care (groups B and C) - Comparator #2: no further follow-up (group D) |
| Antithrombotic therapy | ARTEc | 222 | DAPT vs. SAPT (aspirin) | Sapien XT | All-cause death, MI, ischemic stroke/TIA or life-threatening/major bleeding | 3-month composite endpoint - DAPT: 15.3% - SAPT: 7.2% (P=0.065) |
| | GALILEO [NCT02556203] | 1,644 | NOAC (rivaroxaban) vs. DAPT | Any approved device | Death, first thromboembolic event, first bleeding event | Prematurely halted in October 2018† - Intervention: rivaroxaban+aspirin - Comparator: DAPT followed by SAPT (aspirin alone) [Preliminary analysis] Death or 1st thromboembolic event - Rivaroxaban: 11.4% - DAPT: 8.8% All-cause death - Rivaroxaban: 6.8% - DAPT: 3.3% Primary bleeding - Rivaroxaban: 4.2% - DAPT: 2.4% |
| | ATLANTIS [NCT02664649] | 1,510 | NOAC (apixaban) vs. standard of care (VKA or DAPT) | Any approved device | Composite of death, thromboembolic event, bleeding event | Estimated primary completion date: May 2020 - Stratum 1 (Indication for anticoagulation): apixaban vs. VKA - Stratum 2 (no indication for anticoagulation): apixaban vs. DAPT (followed by SAPT) |
| | ENVISAGE-TAVI AF [NCT02943785] | 1,400 | NOAC (edoxaban) vs. VKA | Any approved device | Composite of death, thromboembolic event, bleeding event | Estimated primary completion date: May 2020 - Intervention: edoxaban with or without APT - Comparator: VKA with or without APT |
| Low Risk TAVR | [NCT03557242] | 300 | VKA with aspirin vs. SAPT (aspirin) | Any approved device | All-cause death, all stroke, life-threatening and major bleeding, major vascular complications, hospitalization for valve-related symptoms or worsening HF, hypo-attenuated leaflet thickening, at least moderately restricted leaflet motion, hemodynamic dysfunction | Estimated primary completion date: July 2023 - Intervention: VKA with aspirin - Comparator: aspirin monotherapy - Registry arm: indication for anticoagulation |

(Table 1 continued the next page.)
The height of coaptation of bicuspid AV can be higher than that of usual tricuspid AV, and the degenerative changes in bicuspid AV result in fibrosis and calcification of the redundant AV cusps, further increasing the cusp height. It means that the main radial resistance from the bicuspid AV leaflets does not directly affect the level of prosthetic AV annulus level but rather the level 4–5 mm higher than the annulus. Therefore, determining the device size and deployment procedures (i.e., balloon pre- or post-dilation) in bicuspid AV should be different from the usual pre-TAVR planning for tricuspid AS: the supra-annular structure, together with the actual opening size of native bicuspid AV leaflets, should be considered. For short devices, prosthetic AV leaflets are to be placed at the same level as the native AV annulus, through a direct tear of the bicuspid AV leaflets. However, for long self-expanding devices, such as Evolut-R and Evolut-PRO, the sizing of the device needs special considerations.

*The Low Risk TAVR trial enrolled 200 low-risk patients with symptomatic severe AS and compared outcomes with an inverse probability weighting-adjusted control cohort of 719 patients who underwent SAVR at the same institutions using the STS database.†The GALILEO trial [NCT02556203] was designed to compare standard DAPT vs. apixaban in TAVR patients without atrial fibrillation. However, the trial was prematurely halted in October 2018, because of concerns regarding the bleeding risk. APT, antiplatelet therapy; AS, aortic stenosis; AV, aortic valve; CT, computed tomography; DAPT, dual antiplatelet therapy; HF, heart failure; MI, myocardial infarction; NOAC, non-vitamin K antagonist oral anticoagulant; SAPT, single antiplatelet therapy; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement; TIA, transient ischemic attack; VARC, Valve Academic Research Consortium; VKA, vitamin K antagonist.

**Figure 2.** Current recommendations for selecting transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) summarized from the guidelines of the AHA/ACC (Upper) and the ESC/EACTS (Lower). AS, aortic stenosis; CAD, coronary artery disease; MV, mitral valve; TV, tricuspid valve.
in patients with a small aortic annulus or in Asian patients has been addressed and should not serve as a barrier against TAVR.

**Novel Indications of TAVR**

**TAVR for AR**

Although several case reports and small studies suggested the feasibility of TAVR for aortic regurgitation (AR), early studies showed lower success rate and higher mortality risk compared with the outcomes of SAVR, because of the anatomic differences between AS and AR.

In patients with AS, heavy deposition of calcium on native AV leaflets and commissures serve to anchor the prosthesis. In contrast, patients with AR have minimal or absent calcification of AV leaflets, and have a dilated aortic root and ascending aorta. These anatomic features are obstacles to TAVR procedures, including suboptimal visualization of AV on fluoroscopy during the procedure and insufficient device anchoring, leading to a higher risk of device dislocation and residual AR.

Considering that anchoring of the device is the key issue in TAVR for AR, several new-generation devices with innovative anchorage mechanisms demonstrate promising results (Figure 4). With the use of these new-generation devices, TAVR for severe AR might be a technically feasible treatment option.

---

**Figure 3.** Representative cases of measurement of eccentricity of aortic valve (AV) calcification (EoC). It can be quantified by a leaflet-based method (Middle column), but might underestimate the true EoC, especially in those with bicuspid AV (A), balanced calcification of 3 AV leaflets (B), or with marked commissural calcification (C). In contrast, the “bipartition EoC” is a simple and precise reflection of the true EoC in severe AS compared with the conventional “leaflet-based EoC” (Right column).
Current Issues in TAVR and Paradigm Shift

4.8%. The extrapolation of currently available data enables an optimistic expectation of the long-term durability of TAVR.

Leaflet Thrombosis
Durability issues for TAVR also include the development of leaflet thrombosis. Makkar et al collected CT scan images of 55 patients who underwent TAVR from an ongoing trial and of 132 patients from registries of either TAVR or SAVR and found that 40% of patients from the trial and 13% of patients from the registries had reduced leaflet motion on CT. An analysis of CT images of 890 patients...
with a bioprosthetic AV reported that the incidence of subclinical leaflet thrombosis was 4% in SAV and 13% in TAV. Compared with complete resection of native leaflets and uniform expansion of the bioprosthesis in SAVR, the transcatheter procedure may cause traumatic injury to the pericardial leaflets and incomplete expansion or overexpansion of the device, resulting in a higher incidence of subclinical leaflet thrombosis.

From the studies that reported subclinical leaflet thrombosis after TAVR, there was an interesting finding that anticoagulant use, compared with dual antiplatelet therapy, was associated with a lower risk of thrombosis development. That finding suggested a preventive effect of anticoagulation against the development of leaflet thrombosis and overt valve dysfunction after TAVR. Several ongoing trials will provide concrete evidence on the appropriate antithrombotic treatment after TAVR (Table 1).

Furthermore, because the development of leaflet thrombosis is one of the main concerns regarding durability, the results of these trials will contribute to an improvement of the durability of TAV.

**Valve-in-Valve Procedures and Long-Term Management Strategy**

**Age and Deciding Between TAVR and SAVR**

The therapeutic strategy for severe AS can be summarized as the ratio between life expectancy and valve durability.
Because of the peri-operative risk, older patients may prefer TAVR, avoiding open heart surgery. In contrast, younger patients may prefer a strategy that can avoid reintervention, placing higher value on long-term durability of the prosthesis. Current guidelines suggest the age of 75 years as a provisional criterion. For example, in patients with life expectancy <10 years (i.e., aged ≥75 years), TAVR would be the rational therapeutic approach, because the bioprosthesis has an expected durability of up to 10 years. In contrast, in patients with life expectancy over 15–20 years (i.e., aged <75 years), SAVR can be an appropriate option. However, the age of 75 years is an arbitrary cutoff, as there is limited evidence on the outcomes of TAVR in younger patients. Therefore, blindly following this age cutoff may be inappropriate in a society where life expectancy is exceptionally long (i.e., Japan), or in younger patients who have high surgical risk or have other factors not included in the risk scoring calculators but which may increase the risk of surgery. Several studies show that the outcomes of younger patients (age <75 years) were similar between SAVR and TAVR, despite the higher incidence of comorbidities among those who underwent TAVR. These optimistic results require further confirmation in large-scale randomized trials, and the cutoff age of 75 years may be downgraded with ongoing trials addressing the long-term durability of TAVR.

**ViV-TAVR as Bailout Strategy for Failed Surgical Bioprosthesis**

As a treatment plan for bioprosthetic valve failure, redo-SAVR has long been considered the only available treatment, despite the high risk of mortality and morbidity. However, there has been a breakthrough with valve-in-valve (ViV) TAVR. Generally, SAV has support structures such as a stent or frame, which is attached to a basal ring covered by a fabric sewing cuff (Supplementary Figure 3). These structural features should be considered during ViV-TAVR. Unlike the native stenotic AV, the SAV is less elliptical, has a stiffer, non-expandable landing zone because of the stent or frame, a smaller internal diameter, and less consistent friction on the new transcatheter device, which poses a risk of post-deployment movement towards LV or aorta. Therefore, this bailout procedure needs special considerations, as summarized in Table 2.

According to registries of high-risk patients who underwent ViV-TAVR for failed SAV, the 1-month mortality was 2.7–7.6% and the 1-year mortality was 12.4–16.8%. As an alternative treatment option for failed SAV, the outcomes of ViV-TAVR should be compared with those of redo-SAVR. A recent meta-analysis demonstrated similar procedural mortality and 30-day mortality between the 2 therapeutic measures. The potential benefits of redo-SAVR over ViV-TAVR were superior echocardiographic outcomes, lower PPM incidence, and lower occurrence of PVL. In contrast, ViV-TAVR showed better outcomes than redo-SAVR in terms of a lower rate of permanent pacemaker implantation, shorter stay in intensive care unit, and shorter hospital stay. Furthermore, a recent study from the STS/ACC registry reported lower mortality rate and less HF hospitalizations in the ViV-TAVR group, compared with those who underwent TAVR for a native valve. Based on these results suggesting that ViV-TAVR is a feasible alternative to redo-SAVR in patients with failed SAV, the ViV-TAVR has been approved in the USA, Europe, and many other countries. In Japan, ViV-TAVR with Evolut-R for failed SAV was approved in 2018.

**ViV-TAVR as Rescue of Failed Transcatheter Bioprosthesis**

Because TAV can degenerate in a manner similar to that of SAV, ViV application in failed TAV is also a treatment option. Since the early TAVR era, this “Russian doll concept procedure” has been a feasible rescue treatment with high success rates in cases of TAV malposition, moderate or severe PVL, or intravalvular regurgitation. According to a recent study, the late survival rate was 85.1% at a median follow-up of 4.4 years after index TAVR and 1.7 years after ViV-TAVR for TAV, and the hemodynamic outcome was favorable. Considering the acceptable outcomes of ViV-TAVR and the rapidly growing population of patients with TAV, ViV-TAVR holds promise for wider use.

**New Paradigm for Young Patients With AS**

The clinical role of TAVR is currently being applied in patients for whom previously SAVR was recommended; that is, those with severe AS and low surgical risk; bicuspid AV; moderate AS with HF; severe AR; and bioprosthetic valve failure. Also, given the acceptable outcomes demonstrated in numerous studies, ViV-TAVR will not just...
remain as a rescue treatment, but can be incorporated in the management strategies of severe AS, when long-term durability is provided. Currently, the management strategy for severe AS is mainly determined by the estimated risk scores (Figure 5A). The initial treatment of choice is SAVR for low-risk patients, SAVR or TAVR for intermediate-risk patients, and TAVR for high surgical risk and inoperable patients. For those with bioprosthetic valve failure, redo-SAVR or ViV-TAVR can be considered. However, if the advantages of TAVR outweigh the expected results from conventional SAVR, it is possible that the overall treatment strategy will change (Figure 5B). Given the comparable or even better outcomes of TAVR than SAVR among low-risk patients, the initial treatment of choice would be TAVR regardless of the estimated risk scores, if the long-term durability of TAVR is proved to be comparable to that of SAVR. Similarly, if the clinical outcomes of ViV-TAVR are comparable to those of redo-SAVR, then ViV-TAVR can be used instead of redo-SAVR at the time of TAV structural deterioration. Thereafter, patients may need SAVR, followed by ViV-TAVR for SAVR, if the replaced bioprosthesis deteriorates. To date, there have been several reports in which TAVR was performed for young patients with severe AS, because of multiple previous surgeries for congenital heart disease, or severe comorbid diseases that render the patient inoperable. Apart from previous heart surgery or severe comorbid diseases, the treatment of choice for young patients is SAVR, and the above suggested approach (Figure 5B) require much more evidence on very long-term outcomes. Nonetheless, recent studies supporting TAV durability suggest that TAV might replace conventional SAVR in certain patients with severe AS regardless of the calculated risk scores. The major paradigm shift for TAVR, in terms of replacing the current role of SAVR and incorporating ViV-TAVR procedures into the treatment algorithm, can be considered a reasonable new direction (Figure 6).

Conclusions

In this review, we have discussed whether TAVR could play a major therapeutic role as an alternative to SAVR. The efficacy and safety of TAVR have been investigated in numerous studies of patients with severe AS and a wide spectrum of surgical risk. The overall outcomes of TAVR were comparable with, or even superior to, those of SAVR, especially among those with intermediate and high surgical risk. Furthermore, recent trials showed similar or even better outcomes of TAVR in low-risk patients, compared with SAVR. Based on consistent evidence, TAVR is replacing the clinical role of SAVR, and its indications are expanding to various patient populations with AV disease, including bicuspid AS, moderate AS with HF, severe AR, and bioprosthetic valve failure. A major paradigm shift in the treatment of AV disease is already in progress, and future studies are needed to clarify the optimal treatment strategy for applying TAVR in patients with various AV diseases.

Funding Sources

This study was supported by a grant of Korea Health Technology R&D Project (HI 17C2085 & HI14C1277) through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare (MHW), Republic of Korea.

Disclosures

None.

References

1. Fenn J, Raskino M. Mastering the hype cycle: How to choose the right innovation at the right time. Brighton, MA: Harvard Business Press, 2008; 25–46.
2. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC Guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017; 70: 252–289.
3. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017; 38: 2739–2791.
4. Kapadia SR, Leon MB, Makkar RR, Tuzcu EM, Svensson LG, Kodali S, et al. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): A randomised controlled trial. Lancet 2015; 385: 2477–2484.
5. Mack MJ, Leon MB, Smith CR, Miller DC, Moses JW, Tuzcu EM, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): A randomised controlled trial. Lancet 2015; 385: 2477–2484.
6. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016; 374: 1609–1620.
7. Reardon MJ, Adams DH, Kleiman NS, Yakubov SJ, Coselli JS, Deeb GM, et al. 2-Year outcomes in patients undergoing surgical or self-expanding transcatheter aortic valve replacement. J Am Coll Cardiol 2015; 66: 113–121.
8. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, Leon MB, et al. Surgical versus transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 2017; 376: 1321–1331.
9. Sondergaard L, Steinbruchel DA, Ilehnann N, Nissen H, Kjeldsen BJ, Petrusson P, et al. Two-year outcomes in patients with severe aortic valve stenosis randomized to transcatheter versus surgical aortic valve replacement: The All-Comers Nordic Aortic Valve Intervention Randomized Clinical Trial. Circ Cardiovasc Interv 2016; 9: e003665.
10. Waksman R, Rogers T, Torguson R, Gordon P, Ehsan A, Wilson SR, et al. Transcatheter aortic valve replacement in low-risk patients with symptomatic severe aortic stenosis. J Am Coll Cardiol 2018; 72: 2095–2105.
11. Sondergaard L, Ilehnann N, Capodanno D, Jorgensen TH, Nissen H, Kjeldsen BJ, et al. Durability of transcatheter and surgical bioprosthetic valve replacements in patients at lower surgical risk. J Am Coll Cardiol 2019; 73: 546–553.
12. Popma JJ, Deeb GM, Yakubov SJ, Muntaz M, Gada H, O’Hair D, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med, doi:10.1056/NEJMoa1816885.
13. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med, doi:10.1056/NEJMoa1814052.
14. Allali J, Laack S, Kim DH, Lefèvre T, Piazza N, Lachapelle K, et al. Frailty in older adults undergoing aortic valve replacement: The FRAILTY-AVR Study. J Am Coll Cardiol 2017; 70: 689–700.
15. Shimura T, Yamamoto M, Kano S, Kagase A, Kodama A, Koyama Y, et al. Impact of frailty markers on outcomes after transcatheter aortic valve replacement: Insights from a Japanese multicenter registry. Ann Cardiothorac Surg 2017; 6: 532–537.
16. Shimura T, Yamamoto M, Kano S, Hosoba S, Sago M, Kagase A, et al. Patients refusing transcatheter aortic valve replacement even once have poorer clinical outcomes. J Am Heart Assoc 2018; 7: e009195.
17. Khalique OK, Hahn RT, Gada H, Nazif TM, Vahl TP, George I, et al. Quantity and location of aortic valve complex calcification predicts severity and location of paravalvular regurgitation and frequency of post-dilation after balloon-expandable transcatheter aortic valve replacement. JACC Cardiovasc Interv 2014; 7: 885–894.
18. Park JB, Hwang IC, Lee W, Han JK, Kim CH, Lee SP, et al. Quantified degree of eccentricity of aortic valve calcification predicts risk of paravalvular regurgitation and response to balloon post-dilation after self-expandable transcatheter aortic valve replacement. *Int J Cardiol* 2018; 259: 60–68.

19. Hayashida K, Bouvier E, Levefre T, Hovasse T, Morice MC, Chevalier B, et al. Potential mechanism of annulus rupture during transcatheter aortic valve implantation. *Catheter Cardiovasc Interv* 2013; 82: E74–E746.

20. Schafers HJ, Schmied W, Marom G, Aicher D. Cusp height in aortic valves. *J Thorac Cardiovasc Surg* 2013; 146: 269–274.

21. Hayashida K, Bouvier E, Levefre T, Chevalier B, Hovasse T, Romano M, et al. Transcatheter aortic valve implantation for patients with severe bicuspid aortic valve stenosis. *Circ Cardiovasc Interv* 2013; 6: 284–291.

22. Yoon SH, Bleiziffer S, De Backer O, Delgado V, Arai T, Ziegelmüller J, et al. Outcomes in transcatheter aortic valve replacement for bicuspid versus tricuspid aortic valve stenosis. *J Am Coll Cardiol* 2017; 69: 2579–2589.

23. Herrmann HC, Daneshvar SA, Fonorow GC, Stebbins A, Vemulapalli S, Desai ND, et al. Prosthesis-patient mismatch in patients undergoing transcatheter aortic valve replacement. From the STS/ACC TVT Registry. *J Am Coll Cardiol* 2018; 72: 2701–2711.

24. Pibarot P, Weissman NJ, Stewart WJ, Hahn RT, Lindman BR, McAndrew T, et al. Incidence and sequelae of prosthesis-patient mismatch in transcatheter versus surgical valve replacement in high-risk patients with severe aortic stenosis: A PARTNER trial cohort-a analysis. *J Am Coll Cardiol* 2014; 64: 1323–1334.

25. Kamperidis V, van Rosendael PJ, de Weger A, Katsanos S, Regeer M, van der Kley F, et al. Surgical sutureless and transcatheter aortic valves: Hemodynamic performance and clinical outcomes in propensity score-matched high-risk populations with severe aortic stenosis. *JACC Cardiovasc Interv* 2015; 8: 670–677.

26. Kalavrouziotis D, Rodes-Cabau J, Bagur R, Doyle D, De Larochelliere R, Pibarot P, et al. Transcatheter aortic valve implantation in patients with severe aortic stenosis and small aortic annulus. *J Am Coll Cardiol* 2011; 58: 1016–1024.

27. Miyasaka M, Tada N, Taguri M, Kato S, Enta Y, Oтомoto T, et al. Incidence, predictors, and clinical impact of prosthesis-patient mismatch following transcatheter aortic valve replacement in Asian patients: The OCEAN-TAVI registry. *JACC Cardiovasc Interv* 2018; 11: 771–780.

28. Yashima F, Yamamoto M, Tanaka M, Yanagisawa R, Arai T, Shimizu H, et al. Transcatheter aortic valve implantation in patients with an extremely small native aortic annulus: The OCEAN-TAVI registry. *Int J Cardiol* 2017; 240: 126–131.

29. Franzone A, Piccolo R, Siontis GC, Lanz J, Stortecky S, Praz F, et al. Transcatheter aortic valve replacement for the treatment of pure native aortic valve regurgitation: A systematic review. *JACC Cardiovasc Interv* 2016; 9: 2308–2317.

30. Yoon SH, Schmidt T, Bleiziffer S, Schofer N, Fiorina C, Munoz-Garcia AJ, et al. Transcatheter aortic valve replacement in pure native aortic valve regurgitation. *J Am Coll Cardiol* 2017; 70: 2752–2763.

31. van Gils L, Clavel MA, Vollema EM, Hahn RT, Spitzer E, Delgado V, et al. Prognostic implications of moderate aortic stenosis in patients with left ventricular systolic dysfunction. *J Am Coll Cardiol* 2017; 69: 2383–2392.

32. Clavel MA, Berthelot-Richer M, Le Ven F, Capoulade R, Dahou A, Dumensil JG, et al. Impact of classic and paradoxical low flow on survival after aortic valve replacement for severe aortic stenosis. *J Am Coll Cardiol* 2015; 65: 645–653.

33. Levy F, Laurent M, Monin JL, Maillet JM, Pasquet A, Le Tourneau T, et al. Aortic valve replacement for low-flow/low-gradient aortic stenosis operative risk stratification and long-term outcome: A European multicenter study. *J Am Coll Cardiol* 2008; 51: 1466–1472.

34. Ribeiro HB, Larakis S, Gilard M, Cavalcante JL, Makkar R, Herrmann HC, et al. Transcatheter aortic valve replacement in patients with low-flow, low-gradient aortic stenosis: The TOPAS-TAVI registry. *J Am Coll Cardiol* 2018; 71: 1297–1308.

35. Bagur R, Pibarot P, Otto CM. Importance of the valve durability-life expectancy ratio in selection of a prosthetic aortic valve. *Heart* 2017; 103: 1756–1759.

36. Martin C, Sun W. Comparison of transcatheter aortic valve and surgical bioprosthetic valve durability: A fatigue simulation study. *Biomotech* 2015; 48: 3026–3034.

37. Douglas PS, Leon MB, Mack MJ, Svensson LG, Webb JG, Hahn RT, et al. Longitudinal hemodynamics of transcatheter and surgical aortic valves in the PARTNER trial. *JAMA Cardiol* 2017; 2: 1197–1206.

38. Barbanti M, Petronio AS, Etorri F, Latib A, Bedogni F, De Marco F, et al. 5-Year outcomes after transcatheter aortic valve implantation with corevalve prosthesis. *JACC Cardiovasc Interv* 2015; 8: 1084–1091.

39. Barbanti M, Costa G, Zappulla P, Todaro D, Picci A, Rapisarda G, et al. Incidence of long-term structural valve dysfunction and bioprosthetic valve failure after transcatheter aortic valve replacement. *J Am Heart Assoc* 2018; 7: e008440.

40. Makkar RR, Fontana G, Jilaihawi H, Chakravarty T, Kofoid KF, De Backer O, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. *N Engl J Med* 2015; 373: 2015–2024.

41. Chakravarty T, Sondergaard L, Friedman J, De Backer O, Berman D, Kofoid KF, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: An observational study. *Lancet* 2017; 389: 2383–2392.

42. Frank D, Abdel-Wahab M, Gilard M, Digne F, Souteyrand G, Causin C, et al. Characteristics and outcomes of patients ≤75 years who underwent transcatheter aortic valve implantation: Insights from the SOURCE 3 Registry. *Circ Rev Cardiol*, doi: 10.1007/s00392-019-1404-2.

43. Eggebrecht H, Besthorn K, Rassaf T, Besthorn M, Voigtlander T, Fleck E, et al. In-hospital outcomes after transcatheter or surgical aortic valve replacement in younger patients less than 75 years old: A propensity-matched comparison. *EuroIntervention* 2017; 14: 50–57.

44. Dvir D, Webb JG, Bleiziffer S, Pasic M, Waksman R, Kodali S, et al. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. *JAMA* 2014; 312: 162–170.

45. Webb JG, Mack MJ, White JM, Dvir D, Blanke P, Herrmann HC, et al. Transcatheter aortic valve implantation within degenerated aortic surgical bioprostheses: PARTNER 2 Valve-in-Valve Registry. *J Am Coll Cardiol* 2017; 69: 2253–2262.

46. Gozdek M, Raffa GM, Suwalski P, Kolodziejczak M, Anisimowicz L, Kubica J, et al. Comparative performance of transcatheter aortic valve-in-valve implantation versus conventional surgical redo aortic valve replacement in patients with degenerated aortic valve bioprostheses: Systematic review and meta-analysis. *Eur J Cardiothorac Surg* 2018; 53: 495–504.

47. Tuzcu EM, Kapadia SR, Vemulapalli S, Carroll JD, Holmes DR Jr, Mack MJ, et al. Transcatheter aortic valve replacement of degenerated surgical bioprosthetic aortic valves: An observational study. *Circ Cardiovasc Interv* 2016; 9: e003930.

48. Panoulias VF, Sutaria N, Sen S, Frame A, Ariff B, Gopalan D, et al. Transcatheter aortic valve implantation in the very young patient. *Rev Port Cardiol* 2013; 32: 827–831.

49. Rodes-Cabau J, Masson JB, Welsh RC, Garcia Del Blanco B, Pelletier M, Webb JG, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: The ARTE (Aspirin Versus Aspirin+Clopidogrel Following Transcatheter Aortic Valve Implantation) randomized clinical trial. *JACC Cardiovasc Interv* 2017; 10: 1357–1365.

Supplementary Files
Please find supplementary file(s):
http://dx.doi.org/10.1016/j.circj.2019-04-0066